Yandong Qiang, MD, PhD, MPH, MHS

FDA

Poster(s):

• ((A-315)) (A-315) Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors, Sodium Glucose Cotransporter 2 Inhibitors, or Sulfonylurea in the U.S. Food and Drug Administration’s Sentinel System
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((A-316)) (A-316) Risk of Diabetic Ketoacidosis Across Stages of Chronic Kidney Disease in Patients with Type 1 Diabetes in the U.S. Food and Drug Administration’s Sentinel System
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((B-091)) (B-091) Utilization of Type 2 Diabetes Mellitus Products in the Sentinel Distributed Database, 2008-2024
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• ((C-077)) (C-077) Use of Glucagon-Like Peptide-1 Receptor Agonists in the U.S. Food and Drug Administration’s Sentinel System
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET